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Vaccination with Klebsiella pneumoniae-derived
extracellular vesicles protects against bacteria-induced
lethality via both humoral and cellular immunity
Won-Hee Lee1, Hyun-Il Choi1, Sung-Wook Hong1, Kwang-sun Kim2, Yong Song Gho1 and Seong Gyu Jeon3
The emergence of multidrug-resistant Klebsiella pneumoniae highlights the need to develop preventive measures to ameliorate
Klebsiella infections. Bacteria-derived extracellular vesicles (EVs) are spherical nanometer-sized proteolipids enriched with outer
membrane proteins. Gram-negative bacteria-derived EVs have gained interest for use as nonliving complex vaccines. In the
present study, we evaluated whether K. pneumoniae-derived EVs confer protection against bacteria-induced lethality.
K. pneumoniae-derived EVs isolated from in vitro bacterial culture supernatants induced innate immunity, including the
upregulation of co-stimulatory molecule expression and proinﬂammatory mediator production. EV vaccination via the
intraperitoneal route elicited EV-reactive antibodies and interferon-gamma-producing T-cell responses. Three vaccinations with
the EVs prevented bacteria-induced lethality. As veriﬁed by sera and splenocytes adoptive transfer, the protective effect of
EV vaccination was dependent on both humoral and cellular immunity. Taken together, these ﬁndings suggest that
K. pneumoniae-derived EVs are a novel vaccine candidate against K. pneumoniae infections.
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INTRODUCTION
Klebsiella pneumoniae is a Gram-negative, encapsulated,
facultative anaerobic bacterium, which is found in the normal
ﬂora of the mouth, skin and intestine.1 The most common
infection caused by the Klebsiella bacterium outside of hospitals
is pneumonia, typically in the form of bronchopneumonia and
bronchitis.2 K. pneumoniae can cause destructive changes to the
human lungs via inﬂammation and hemorrhage, which can
produce a thick, bloody, mucoid sputum.3 This bacterium
gains access to the lower respiratory tract typically after a
person aspirates microbes that colonize the oropharyngeal
mucosa. Klebsiella infections are observed mostly in people
with a weakened immune system and cause a high death rate of
~ 50%, even with antimicrobial therapy.4,5 In addition to
pneumonia, K. pneumoniae can also cause infections in the
urinary tract, lower biliary tract and surgical wound sites.6–8 In
recent years, K. pneumoniae has become an important patho-
gen in nosocomial infections. Intense antibiotic use is a factor
that increases the risk of nosocomial infection with Klebsiella
bacteria, which are often resistant to multiple antibiotics.9,10
Fatal infections caused by multidrug-resistant K. pneumoniae
have created a pressing need to develop a preventive measure
to ameliorate Klebsiella infections.
Vaccination is the administration of antigenic material to
produce protective immunity to a disease. Vaccination is
regarded as the most cost-effective method for preventing
infectious diseases. This approach requires the induction of
protective immunity, which is best achieved using an active
immunization strategy with the ability to induce speciﬁc
long-term protective memory, the hallmark of adaptive
immunity. The key to eradicate pathogenic bacterial infections
is the activation of speciﬁc immune responses, such as humoral
(or antibody-mediated) and cellular (or T-cell-mediated)
immunity. Gram-negative bacteria-derived extracellular vesicles
(EVs), otherwise known as outer membrane vesicles, are
spherical bilayered phospholipids 20–200 nm in diameter that
harbor many proteins related to pathogenesis.11–13 Biochemical
and proteomic studies have revealed that bacterial EVs are
composed of outer membrane proteins, lipopolysaccharide,
outer membrane lipids, periplasmic proteins, DNA, RNA and
1Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea; 2Superbacteria Research Center,
Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea and 3Research Institute, AEON Medix, Inc, Pohang,
Republic of Korea
Correspondence: Dr SG Jeon, Research Institute, AEON Medix, Inc., Biotech center, POSTECH, 67 Cheongam-ro, Nam-gu, Pohang 790-784, Republic of
Korea.
E-mail: sgjeon@aeonmedix.com
Received 25 April 2015; revised 20 May 2015; accepted 22 May 2015
Experimental & Molecular Medicine (2015) 47, e183; doi:10.1038/emm.2015.59
& 2015 KSBMB. All rights reserved 2092-6413/15
www.nature.com/emm
other factors associated with virulence.14–16 Recent studies have
revealed the potential of EVs derived from Gram-negative
bacteria, such as Neisseria meningitidis, Acinetobacter
baumannii, Porphyromonas gingivalis, Salmonella enterica
serovar Typhimurium, Helicobacter pylori and Vibrio cholerae,
in inducing protective immunity against bacterial infections
in mice.17–25
K. pneumoniae secretes outer membrane vesicles that
can induce the innate immune response.26 Various outer
membrane proteins can be used as the candidate antigens for
vaccine.27–29 In the present study, we evaluated whether
K. pneumoniae-derived EVs elicit a protective effect against
Klebsiella infections. This study showed that vaccination with
K. pneumoniae-derived EVs effectively protected bacteria-
induced lethality in a murine sepsis model. In addition, this
study clariﬁed the underlying mechanisms of how EV vaccina-
tion provides protection against Klebsiella-induced sepsis.
MATERIALS AND METHODS
Mice and cell cultures
Six to seven-week-old female, wild-type C57BL/6 (genetic background
from The Jackson Laboratory, Bar Harbor, ME, USA) were used in the
present study. The experimental protocols were approved by the
Institutional Animal Care and Use Committee at Pohang University of
Science and Technology, Pohang, Republic of Korea with approval
number 2011-01-0017. A total of 2 × 106 Raw 264.7 mouse macro-
phages (purchased from ATCC, Manassas, VA, USA) were cultured
with Dulbecco's Modiﬁed Eagle's medium (DMEM) (Hyclone, Little
Chalfont, UK) containing 10% fetal bovine serum (FBS) and
antibiotics (100 unit ml−1 penicillin and 100 μg ml−1 streptomycin)
in 100mm tissue culture dishes (TPP, Trasadingen, Swiss) at 37 °C
until use in an experiment. Extracted bone marrow-derived dendritic
cells were cultured with Roswell Park Memorial Institute (RPMI) 1640
(Hyclone) containing 10% FBS, 50 μM 2-mercaptoethanol (ME) and
antibiotics (100 unit ml−1 penicillin and 100 μg ml−1 streptomycin).
For the ex vivo experiments, RPMI 1640 (Hyclone) containing 10%
FBS, 50 μM 2-ME, 0.01M 4-(2-hydroxyethyl)-1-piperazineethanesul-
fonic acid and antibiotics (100 unit ml−1 penicillin and 100 μg ml−1
streptomycin) was used to culture the splenocytes.
Bacteria strain and preparation of K. pneumoniae-derived EVs
K. pneumoniae (ATCC 4208) was purchased from ATCC and was
cultured in nutrient broth (Merck, Kenilworth, NJ, USA) at 37 °C
shaking at 200 rpm to an optical density of 1.5. The cultured bacteria
were pelleted twice at 10 000× g for 20min at 4 °C. The supernatants
were ﬁltered using a 0.45-μm bottle top vacuum ﬁlter (Corning,
Corning, NY, USA) and were concentrated with a 100-kDa hollow
ﬁber membrane ﬁlter using the QuixStand Benchtop System (Amer-
sham Biosciences, Little Chalfont, UK). The concentrated solution was
ﬁltered using a 0.22-μm bottle top vacuum ﬁlter (Corning) to remove
any remaining bacteria. The ﬁnal ﬁltered solution was ultracentrifuged
at 150 000× g for 3 h at 4 °C in a type 45 Ti rotor (Beckman
Instruments, Brea, CA, USA). Finally, the EV pellet was re-
suspended in phosphate-buffered saline (PBS) and was quantitated
using the Bradford assay (BIO-RAD, Hercules, CA, USA). The
prepared EVs were stored at − 80 °C until use.30 All EV batch
preparations were performed under the same conditions.
Transmission electron microscopy
The EVs were diluted with PBS, and 10 μl of the suspension
(50 μg ml−1) were dropped on 300-mesh copper grids (EMS, Hatﬁeld,
PA, USA). Uranyl acetate (2%) was then dropped onto the grids to
stain the EVs. The images were captured using a JEM1011 electron
microscope (JEOL, Tokyo, Japan).31
Dynamic light scattering
The EVs were diluted with PBS to 500 ngml−1, and the diameter size
distribution was measured by dynamic light scattering using a
Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) and
Dynamic V6 software.32
Macrophage uptake assay
The EVs were incubated with 2 μM of DiI (Invitrogen, Waltham, MA,
USA) for 1 h and were washed with PBS. The washed EVs were
ultracentrifuged using a TLA 120.2 (Beckman Instruments) at
150 000× g at 4 °C for 3 h. The pellet was re-suspended in PBS. Raw
264.7 mouse macrophages (2× 105 cells per well) were incubated with
DMEM (Hyclone) containing 10% FBS and antibiotics (100 unit ml−1
penicillin and 100 μg ml−1 streptomycin) on a gelatin-coated cover
class in a 24-well cell culture plate for 24 h and were then treated
10 μg ml−1 of EVs for 1 and 6 h with DMEM containing antibiotics
(100 unit ml−1 penicillin and 100 μgml−1 streptomycin). After the
stimulation, the cells were washed with PBS and ﬁxed with 4%
paraformaldehyde. For staining of the cell nucleus, the ﬁxed cells were
treated with 20 μM Hoechst (Sigma-Aldrich, St Louis, MO, USA) and
were mounted on a glass slide. A LSM 510 META laser scanning
microscope (Carl Zeiss, Oberkochen, Germany) was used to acquire
the confocal images.33
In vitro macrophage studies
Raw 264.7 mouse macrophages (5× 105 cells per well) were incubated
with DMEM containing 10% FBS and antibiotics (100 unit ml−1
penicillin and 100 μg ml−1 streptomycin) in a 24-well tissue culture
plate at 37 °C for 24 h. The culture medium was removed and various
doses of EVs (0.1–1000 ng/ml−1) in serum-free media (DMEM)
containing antibiotics (100 unit ml−1 penicillin and 100 μg ml−1
streptomycin) were added. After a 15 h stimulation, the culture
medium was collected and the levels of proinﬂammatory cytokines,
such as interleukin (IL)-6 and tumor necrosis factor-alpha, were
measured.
Expression of cell surface molecules on bone
marrow-derived dendritic cells
To obtain mouse bone marrow-derived dendritic cells, mouse femurs
were extracted and bone marrow was washed with cold PBS using a
sterile syringe on a non-coated petri dish (SPL, Pocheon, Korea). At
day 0, the extracted bone marrow-derived dendritic cells (2× 106 cells
per plate) were cultured with 10ml of RPMI 1640 (Hyclone)
containing 20 ngml−1 of granulocyte-macrophage colony-stimulating
factor (R&D Systems, Minneapolis, MN, USA), 10% FBS, 50 μM
2-ME and antibiotics (100 unit ml−1 penicillin and 100 μg ml−1
streptomycin). At day 3, 10ml of the same culture medium was
added to the plate. At days 6 and 8, 10ml of the culture medium were
collected, and the cells were pelleted by centrifugation. Each pellet was
re-suspended in 10ml of same medium and was added to the plate.
At day 10, the cells were harvested by centrifugation. At day 11, the
cells were transferred to a 24-well tissue culture plate for stimulation.
The prepared cells (5× 105 cells per well in 24-well plate) were
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incubated with RPMI 1641 containing 10% FBS, 50 μM 2-ME and
antibiotics (100 unit ml−1 penicillin and 100 μgml−1 streptomycin).
After 24 h, the culture medium was removed, and then the various
stimulators (lipopolysaccharide (Sigma-Aldrich) 10 100 ngml−1;
EVs 0.1 pgml−1-1000 ngml−1) in serum-free medium (RPMI 1641
containing 2-ME and antibiotics) were added to the cells. After
24 h of stimulation, the cells were stained with anti-CD11c-APC
(BD Biosciences, Franklin Lakes, NJ, USA), anti-CD86-PE
(BD Biosciences), or anti- major histocompatibility complex class II-
ﬂuorescein isothiocyanate (BD Biosciences) antibodies. A FACSCali-
bur (BD Biosciences) instrument was used for ﬂuorescence-activated
cell sorting analysis.13
Lethal dose determinations of K. pneumoniae-induced
bacterial sepsis
For determining the lethal dose of K. pneumonia infections, three
different doses (1× 106, 1 × 107 and 1× 108) of K. pneumoniae strain
in 100 μl of PBS were injected intraperitoneally into mice. The survival
rate was observed every 12 h for 3 days.
Evaluation of the protective effect of vaccination
For conﬁrming the immune response to EVs in vivo, the mice were
injected intraperitoneally with 10, 100 and 1000 ng of K. pneumoniae-
derived EVs in 100 μl of PBS three times for 3 weeks at 1-week
intervals. Seven days after the last immunization, the spleens and
blood were extracted for analysis using re-stimulation assay and to
measure antibody titer, respectively. To conﬁrm the protective effect of
vaccination against bacterial infection, the mice were injected intra-
peritoneally with 0.5, 1 and 2 μg of EVs in 100 μl of PBS for the same
period of time. Seven days after the last immunization, both the
immunized and non-immunized (sham) mice were challenged with
the lethal dose of 1 × 108 colony forming units (CFU) of
K. pneumoniae. The survival rate was observed every 12 h for 3 days.
Splenocyte re-stimulation assay
The extracted spleens were mashed with the plunger of 5-ml syringe
onto a 100 μm cell strainer (BD Biosciences) with washing buffer
(DMEM containing 2.5% FBS and 0.01M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid). The separated spleen cells were treated
with an ammonium chloride solution (STEM CELL, British
Columbia, Canada) for 10min at 4 °C to lyse the red blood cells.
The splenocytes were washed with washing buffer and were then
ﬁltered through a 40 μm cell strainer (BD Biosciences). Finally, the
cells were incubated with RPMI 1640 containing 10% FBS, 50 μM
2-ME, 0.01 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid and
antibiotics (100 unit ml−1 penicillin and 100 μgml−1 streptomycin)
in a 24-well plate (TPP) coated with 1 μg mlml−1 of anti-CD3
(eBioscience, San Diego, CA, USA) and 1 μg ml−1 of anti-CD28
(eBioscience) antibodies for 12 h to re-stimulate the splenic T cells.
Measurement of the EV antibody titer
EVs (100 ng) in 100 μl PBS were coated in a black 96-well plate
(Greiner Bio-one, Monroe, NC, USA) for 24 h at 4 °C. The EV-coated
plate was washed with PBS and blocked with the reagent diluent (PBS
containing 1% BSA; Roche) for 1 h. After washing with PBS, the
extracted naive (sham) and vaccinated mouse blood samples were
centrifuged to separate the serum and cell fractions. The serum was
diluted with the reagent diluent (1:500) and was then incubated in the
EV-coated plate for 2 h. After incubation, the plates were washed and
treated with 200 ngml−1 of horseradish peroxidase-conjugated goat
anti-mouse immunoglobulin G (IgG) antibody (Santa Cruz
Biotechnology, CA, USA) for 2 h. After washing the plates,
the enhanced chemiluminescence substrate (Thermo Scientiﬁc,
Kenilworth, NJ, USA) was added and analyzed using a Victor Wallac
1420 apparatus (PerkinElmer, Waltham, MA, USA).
Intracellular cytokine staining of splenic T cells
For the intracellular cytokine staining assay, the mice were immunized
with three doses (10, 100 and 1000 ng) of K. pneumoniae EVs using
the above protocol. A week after the last immunization, the spleens of
both immunized and non-immunized mice were extracted for use in
the re-stimulation assay. The separated splenocytes were incubated in
48-well plates coated with 1 μg ml−1 of anti-CD3 (eBioscience) and
anti-CD28 (eBioscience) antibodies at 37 °C for 12 h. The splenocytes
were stained with anti-CD3-APC (BD Biosciences) and anti-CD4-
FITC (BD Biosciences) antibodies for 30min at 4 °C followed by
ﬁxation for 10min in 4% paraformaldehyde at room temperature.
The splenocytes were then incubated with antibodies against the
cytokines of interest (anti-interferon (IFN)-γ-PE, anti-IL-17-PE and
anti-IL-4-PE; BD Biosciences) for 30min at room temperature
followed by analysis using a FACSCalibur ﬂow cytometer
(BD Biosciences) with the CELLQuest software.34
Adoptive transfer of sera and splenocytes
The mice were immunized intraperitoneally with 1 μg of EVs three
times for 3 weeks. Seven days after the last immunization, blood and
spleens were extracted. The same method was used to acquire the
serum and splenocytes. The extracted serum (100 μl per mouse) and
splenocytes (1× 108 cells per mouse) were injected intraperitoneally
into naive mice. At 24 h after the injection, 2.5 × 107 and 5× 107 CFU
of the bacteria administered intraperitoneally were used to challenge
the mice transferred with serum, splenocytes or sham (PBS).
The survival rate was observed every 12 h for 3 days
Measurement of cytokines
The cytokine levels secreted from Raw 264.7 cells or mouse-derived
splenocytes were measured using a DuoSet ELISA according to the
manufacturer’s protocol (R&D Systems).
Statistical analysis
The survival curves were compared using the log-rank test. All of the
values are expressed as the mean± s.e.m., and the Student’s t-test was
used to calculate P- values based on comparisons with the appropriate
control.
RESULTS
Characterization of K. pneumoniae-derived EVs
To characterize EVs derived from K. pneumoniae, the EVs were
extracted from the bacterial culture. Transmission electron
microscopy analysis revealed that K. pneumoniae secreted EVs,
which are spherical and contain a lipid-bilayer (Supplementary
Figure 1a). Dynamic light scattering analysis revealed a mean
diameter of 36 nm (Supplementary Figure 1b).
In vitro innate immune response induced by
K. pneumoniae-derived EVs
Host defense relies on the concerted action of both innate
immunity and antigen-speciﬁc adaptive immunity. We ﬁrst
evaluated innate immune responses induced by K. pneumoniae
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EVs. When macrophages were treated with EVs for 1 and 6 h,
the signals against EVs were observed in the cytoplasm of
macrophages, indicating that the EVs were internalized by
antigen-presenting cells (Figure 1a). Moreover, the EV-treated
macrophages efﬁciently induced the production of proinﬂam-
matory cytokines, such as IL-6 and tumor necrosis factor-alpha
(Figure 1b). The treatment of macrophages with EVs induced
an increase in the expression of co-stimulatory major histo-
compatibility complex class II and CD86 molecules (Figure 1c
and Supplementary Figure 2). These results suggested that
K. pneumoniae EVs effectively activate innate immune
responses by antigen-presenting cells, which can prime T cells.
In vivo antibody production induced by vaccination with
K. pneumoniae EVs
To determine the effective dose of EVs for vaccination, we
assessed the effect of EV immunization on the induction of
antigen-speciﬁc antibody and T-cell responses. During the
immunization process, sera were obtained from EV- and
sham-immunized mice, and the EV-reactive IgG titer was also
evaluated (Figure 2a). An increase in K. pneumoniae
EV-reactive IgG was detected after immunization with
10, 100 or 1000 ng of K. pneumoniae EVs. However,
K. pneumoniae EV-reactive IgG was not detected in the sera
from mice immunized with Escherichia coli EVs, whereas E. coli
EV-reactive IgG increased in these mice (Figure 2b). These
ﬁndings indicated that K. pneumoniae EV vaccination induced
the production of IgG antibody speciﬁc for K. pneumoniae EVs.
In vivo T-cell responses induced by K. pneumoniae
EV vaccination
Next, to evaluate EV-speciﬁc T-cell responses, splenocytes were
isolated from EV- and sham-immunized mice 1 week after the
last immunization and were then re-stimulated with anti-CD3
and anti-CD28 antibodies for 12 h. The EV-speciﬁc production
of IFN-γ, the key cytokine produced by Th1 cells, was
enhanced in EV-immunized mice in a dose-dependent manner
vs. the control (Figure 2c). However, EV-speciﬁc production of
IL-17 and IL-4, the key cytokine of Th17 and Th2 cells,
respectively, was not enhanced by vaccination (Figure 2c).
Figure 1 In vitro immunogenicity of K. pneumoniae EVs. (a) Raw 264.7 mouse macrophage uptake of EVs. Row 1 is the non-treated
group. Row 2 and 3 are treated with EVs for 1 and 6 h, respectively. Column 1 shows DiI-stained EVs, column 2 shows the Hoechst-
stained cell nucleus, column 3 shows the merged DiI and Hoechst images, and column 4 are the DIC-merged images. (b) Secreted IL-6
and TNF-α from Raw 264.7 cells stimulated by different doses of EVs measured with ELISA. (n=2; *Po0.05, **Po0.01 and
***Po0.001) (c) The expression of MHC class II and CD86 molecules on the surface of CD11C+ bone marrow-derived dendritic cells.
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We also evaluated EV-speciﬁc T-cell responses using intracel-
lular cytokine staining of splenocytes 12 h after the in vitro
stimulation with anti-CD3 and anti-CD28 antibodies, as shown
in Supplementary Figure 3a. This study showed that the
expression of IFN-γ, IL-17 and IL-4 in CD4+ cells was
enhanced by K. pneumoniae EV immunization vs. sham
immunization (Figures 3a and b). Together, these ﬁndings
suggest that immunization with K. pneumonia-derived EVs
induces a strong Th1, IFN-γ-producing T-cell response in
addition to Th17 and Th2 responses against EV antigens.
Effect of K. pneumoniae-derived EV vaccination on
protection against bacteria-induced sepsis
To test the efﬁcacy of EV vaccination against K. pneumoniae-
induced sepsis, a mouse sepsis model was established
by intraperitoneal injection with the different doses of
K. pneumoniae (Figure 4a, left panel). The lethal dose of
K. pneumoniae in this model was 1× 108 CFU (Figure 4a, right
panel). To verify the ability of K. pneumoniae-derived EVs as an
effective vaccine candidate, we examined the effect of EV
immunization on the development K. pneumoniae-induced
sepsis (Figure 4b, left panel). Mice were injected intraperito-
neally with different doses of the EV vaccine candidate every
week for 3 weeks, were challenged with the lethal dose of
K. pneumoniae (1.0 × 108 CFU) 7 days after the ﬁnal
immunization, and the mice were then monitored every 12 h
for 5 days for survival. All of the mice immunized with sham
died 36 h after the bacteria challenge; however, 80% of the
mice survived after vaccination with 0.5 μg of the EVs and
100% of mice survived after vaccination with 1 μg of the EVs.
An increase in the EV quantity (2 μg) did not improve the
vaccine efﬁcacy (Figure 4b). Therefore, the 1 μg dose was
chosen for the vaccine dosage.
Adoptive transfer of sera and splenocytes for protection
against K. pneumonia-induced lethality
Adoptive transfer is one alternative mean to induce immuniza-
tion. To determine whether antibody-mediated humoral or
T-cell-mediated cellular immunity is important in conferring
the EV-induced vaccination effect, we evaluated the protective
effect of adoptive serum and splenocyte transfers as shown in
Supplementary Figure 3b. Naive mice that received splenocytes
from EV-immunized mice effectively protected the bacteria
with a 100% and 40% survival rate after 2.5× 107 and 5×107
CFU of K. pneumoniae challenge, respectively, whereas 40%
and 0% of mice receiving splenocytes from sham-immunized
mice survived the 2.5 × 107 and 5× 107 CFU challenge,
respectively (Figures 5a and b). In addition, the naive mice
that received sera from EV-immunized mice had an enhanced
ability to survive after K. pneumoniae challenge displaying 70%
and 30% survival rate after 2.5× 107 and 5×107 CFU of
K. pneumoniae challenge, respectively, whereas 40% and 0% of
Figure 2 In vivo immunogenicity of K. pneumoniae EVs. (a) K. pneumoniae EV-reactive IgG antibody in serum from mice immunized with
10, 100, 100 ng of K. pneumoniae EVs. This antibody was measured by ELISA (n=5; *Po0.05, **Po0.01 and ***Po0.001, compared
with PBS group). (b) E. coli EV-reactive and K. pneumoniae EV-reactive IgG antibody in serum from mice immunized with 0.1 and 1 μg of
K. pneumoniae EVs and 1 μg of E. coli EVs (n=5; *Po0.05 and **Po0.01, compared with PBS group). (c) Secreted
IFN-γ, IL-17 and IL-4 from splenocytes with and without stimulation with anti-CD3 and anti-CD28 antibodies. The mice were immunized
with 10, 100, 1000 ng of K. pneumoniae EVs (n=5; *Po0.05 and **Po0.01, compared with the non-stimulated, PBS-injected group).
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mice receiving sera from the sham-immunized mice survived
after the 2.5× 107 and 5× 107 CFU challenge, respectively
(Figures 5a and b). These results suggest that both humoral and
cellular immunity confer the protective effect of K. pneumoniae
EV vaccination.
DISCUSSION
Vaccination is considered to be the most effective and cost-
effective method to prevent infectious diseases. In the present
study, we aimed to evaluate the potential use of K. pneumoniae
EVs as a new vaccine material to prevent lethality by
K. pneumoniae infection. Vaccination with a non-lethal dose
of K. pneumoniae EVs effectively protected against lethal
infection with the same strain of K. pneumoniae via both
humoral and cellular immunity. These protective effects were
accompanied by the involvement of innate and adaptive
immune responses induced by EVs, which included
EV-reactive IgG and IFN-γ-mediated immune responses. These
ﬁndings suggest that native EVs derived from K. pneumoniae
are a novel vaccine candidate for the prevention of
K. pneumoniae infections.
K. pneumoniae is the most common cause of nosocomial
respiratory tract and premature intensive care infections
and the second most frequent cause of Gram-negative
bacteremia.35–37 Many studies have shown increasing resistance
of this pathogen to antibiotics, resulting in an average rate of
1.63 outbreaks every year.35 A variety of preventive measures
have been attempted to reduce this incidence. However,
passive immunization and immunoenhancers were shown to
not be practical for the prevention K. pneumoniae infections.38
Figure 3 Proportion of IFN-γ+, IL-17+ and IL-4+ CD4+ T cells. The mice splenocytes, which were immunized with 10, 100, 1000 ng of
K. pneumoniae EVs three times for 3 weeks at a 1-week interval, were stimulated with anti-CD3 and anti-CD28 antibodies. (a) The graphs
and (b) FACS dot plots of intracellular cytokine staining assay for IFN-γ, IL-17 and IL-4 in splenic CD4+ T cells. CD3+, CD4+ and
cytokine-positive splenocytes were gated using APC, FITC and PE, respectively (n=3; *Po0.05, **Po0.01 and ***Po0.001, compared
with PBS group).
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During the last 40 years, the construction of effective vaccines
against K. pneumoniae has been attempted on numerous
occasions. Among these efforts, capsular polysaccharide was
targeted as a vaccine antigen, but the variable capsular
polysaccharide serotypes limited their use in vaccine
production.39 The strategy of targeting non-capsular protein
antigens revealed that outer membrane proteins are protective
antigens in the immune response evoked by K. pneumoniae.40
K. pneumoniae EVs may be an ideal vaccine candidate because
they harbor many outer membrane proteins as well as immune
stimulating pathogen-associated molecular patterns, including
lipopolysaccharide. Indeed, the present study showed that
K. pneumoniae EVs effectively protect against lethality induced
by infection of the same strain of K. pneumoniae.
Adjuvant affects the quality and magnitude of immuno-
logical responses. Various adjuvants, including toll-like
receptors 3, 4, 7 and 9 agonists, are used to enhance the
immune response.41 The presence of lipopolysaccharide in EVs
emphasizes the ability of EVs to act as a natural adjuvant, thus
allowing them to serve as potential adjuvant-free vaccine
candidates for the delivery of various poorly immunogenic
subunits.42 The present study also showed that K. pneumoniae
EVs enhance the expression of co-stimulatory molecules
in macrophages and the production of proinﬂammatory
mediators, which indicates that K. pneumoniae EVs have an
adjuvant capacity in T-cell priming.
Antibody or T-cell responses have a key role in host defense
toward Klebsiella infections.43,44 Capsular polysaccharide
from K. pneumoniae induces thymus-independent humoral
immunity.45 Animal experiments indicate that IFN-γ-deﬁcient
mice are more susceptible to bacterial infections compared
with wild-type mice,46,47 which suggests that the Th1-cell
response is important in the protection against bacterial
infections. Furthermore, IL-17-producing Th17 cells are
necessary for vaccine-induced protection against bacterial
Figure 4 Protective effect of K. pneumoniae EV immunization against K. pneumoniae infection. (a) Survival graph for determining the
lethal dose of K. pneumoniae. Various doses (1×105, 1×106, 1×107 and 1×108 CFU) of bacteria were injected intraperitoneally into
mice (n=10; *Po0.05 and **Po0.01, compared with the PBS-injected group). (b) Survival graph of 1×108 CFU of K. pneumoniae
challenged mice after immunization with 0.5, 1 and 2 μg of K. pneumoniae EVs three times for 3 weeks at a 1-week interval (n=10;
***Po0.001, compared with the sham mice group).
Figure 5 Protective effect of adoptive transfer of sera and
splenocytes from K. pneumoniae EV-immunized mice against lethal
K. pneumoniae infection. Challenge with the bacteria was
performed 24 h after the serum or splenocytes were transferred to
the naive mice. Survival graph of serum or splenocyte transferred
mice after challenged with 2.5×107 CFU of bacteria (a) and
5×107 CFU of bacteria (b) (n=10, each group; *Po0.05,
**Po0.01 and ***Po0.001, compared with the sham group).
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infections by enhancing neutrophil recruitment to infection
sites.48,49 These data suggest that protection against bacterial
infections requires both phagocyte recruitment and phagocy-
tosis mainly via Th17 cell and antibody-mediated immunity
and also that the bactericidal activity of phagocytes is mediated
mainly via Th1-cell immunity. Meanwhile, the present study
showed that K. pneumoniae EV vaccination conferred protec-
tion against K. pneumoniae infection, which was dependent on
both humoral and cellular immunity. Note that K. pneumoniae
EV vaccination induces the production of IFN-γ more than
that of IL-4 and IL-17 from T cells. These ﬁndings suggest
that K. pneumoniae EV vaccination protects against bacterial
infections mainly via both antibody and IFN-γ-mediated
immune responses.
To the best of our knowledge, this is the ﬁrst study to
demonstrate K. pneumoniae EVs as a vaccine candidate against
K. pneumoniae infections. Recently, we also found that E. coli
EVs effectively protect against bacteria-induced sepsis.13
Although the details of the mechanism underlying protection
by EV vaccines still needs to be unraveled, the present
study provides new insight for a novel strategy of vaccine
development using Gram-negative bacteria-derived EVs to
protect against bacterial infections, especially those caused by
multi-drug-resistant bacteria.
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